🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 17 of 173

  1. US 11834512

    Inhibiting anti-ENPP1 antibodies

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11834640

    Device and uses thereof for treating diabetes

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11834499

    Claudin18 antibodies and methods of treating cancer

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11833172

    Use of microRNA-146A and nanoceria conjugate to improve wound healing and promote tissue regeneration

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11833196

    Compositions and methods for delivery of biomacromolecule agents

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11833148

    Methods for treating or limiting development of cardiovascular disease-related neurological disorders

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11833210

    ASH1L inhibitors and methods of treatment therewith

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11834451

    Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11832924

    Fluorescence imaging processing and computation for surgery

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11834413

    Antiplatelet drugs and uses thereof

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11826422

    Methods and compositions for adaptive immune modulation

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11826332

    Antimicrobial compositions and uses thereof

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11826469

    Polymer particles for neutrophil injury

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11826408

    CD200 inhibitors and methods of use thereof

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11827683

    Bi-functional anti-tau polypeptides and use thereof

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11825808

    Mollusk-killing biopesticide

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11825839

    Cryopreservation of cell-seeded substrates and related methods

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11826491

    Compositions and methods for improving cardiac function

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11819523

    Compositions and methods for C. difficile treatment

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11819516

    Immunotherapy

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11819276

    Hyperspectral imaging for early detection of Alzheimer's disease

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11820749

    Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11813358

    Lipid nanodisc formation by polymers having a pendant hydrophobic group

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11813277

    Methods and agents for modulating inflammation

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11814659

    Tunable nanoscale cages from self-assembling DNA and protein building blocks

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11813377

    Microfiber structures and methods of synthesis and use thereof

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11813123

    Ultrasound responsive micro-composite markers

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11814624

    Targeted non-viral DNA insertions

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11814645

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11807661

    Antibody fusion protein and related compositions for targeting cancer

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11806385

    Biomarkers for monitoring immune transformation

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11806432

    Compositions, methods and uses for thermally stable multi-targeted antigens

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11806367

    Methods of treating lysosomal disorders

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11806318

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11801295

    Immunogenic compositions and uses thereof

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11801218

    Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11801269

    Compositions and methods for transplantation of colon microbiota

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11802272

    Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11802138

    Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11795457

    Compositions and methods for treatment of Friedreich's Ataxia

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11793825

    Biomarkers for predicting responsiveness to decitabine therapy

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11793177

    Animal model of Angelman Syndrome

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11786582

    Human application of engineered chimeric antigen receptor (CAR) T-cells

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11786548

    Trace element compositions, methods of making and use

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11786635

    Extracellular matrix for treating pelvic floor disorders and skeletal muscle degeneration

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11786560

    Immunoisolation device

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11787799

    Potent antiviral pyrazolopyridine compounds

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.